methodologies and occurs through a trifluoroacyl radical mechanism promoted by a photocatalyst, which triggers a C−O bond fragmentation. Mechanistic studies (kineticisotopeeffects, spectroelectrochemistry, optical spectroscopy, theoretical investigations) highlight the evidence of a fleeting CF3CO radical under photoredox conditions. The trifluoroacyl radical can be stabilized under CO atmosphere, delivering
我们报告了一种温和且操作简单的烯烃三氟酰化策略,该策略利用三氟乙酸酐作为低成本且易于获得的试剂。这种光介导的过程与传统方法有着根本的不同,它通过由光催化剂促进的三氟酰基自由基机制发生,从而触发 CO 键断裂。机理研究(动力学同位素效应、光谱电化学、光谱学、理论研究)突出了转瞬即逝的 CF 3的证据光氧化还原条件下的 CO 自由基。三氟酰基自由基可以在 CO 气氛下稳定,提供具有更高化学效率的三氟乙酰化产物。此外,该方法可以通过简单地改变反应参数变成三氟甲基化协议。除了简单的烯烃外,该方法还允许小分子药物和常见药效团的化学和区域选择性功能化。
The synthesis of unsaturated trifluoromethyl ketones by regioselective organocuprate addition to acetylemic trifluoromethyl ketones
作者:Russell J. Linderman、Madhu S. Lonikar
DOI:10.1016/s0040-4039(00)96705-4
日期:1987.1
Regiospecific and stereoselective synthesis of unsaturated trifluoromethyl ketones has been accomplished by the addition of higher order cyano cuprates to acetylenic trifluoromethyl ketones.
Pyrazoline derivatives, their preparation and application as medicaments
申请人:Laboratorios del Dr. Esteve, S.A.
公开号:US06353117B1
公开(公告)日:2002-03-05
The present invention relates to new pyazoline derivatives of formula
and to physiologically acceptable salts thereof, to the method for their preparation and to their application as medicaments.
本发明涉及新的吡唑啉衍生物及其生理上可接受的盐,以及它们的制备方法和作为药物的应用。
Development of the Meyer–Schuster Rearrangement on Propargylic Alcohols with Fluorinated Chains
作者:Frédéric Justaud、René Grée
DOI:10.1002/ejoc.202300974
日期:2023.12.13
New enones with mono-, gem-difluoro- or trifluoro chains are easily obtained through the Meyer–SchusterRearrangement (MSR), using phosphomolybdic acid as the catalyst selected after extensive screening.
PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS
申请人:LABORATORIOS DEL DR. ESTEVE, S.A.
公开号:EP1083171A1
公开(公告)日:2001-03-14
The present invention relates to new pyrazoline derivatives having the general formula (I), as well as to their physiologically acceptable salts, to process in human/veterinary therapy and to pharmaceutical compositions containing them. The new compounds of the invention can be used in the pharmaceutical industry as intermediates and for the preparation of medicaments. In particular, they can be used for the preparation of medicaments used for the treatment of inflammation and other troubles associated to inflammation and other process mediated by cyclooxygenase-2, for example arthritis, pain treatment or fever treatment.